A Phase 1, Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2016
At a glance
- Drugs AL 335 (Primary) ; Odalasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 18 Oct 2016 Status changed from recruiting to completed.
- 16 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.
- 16 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2016.